News

Health care stocks were higher late Wednesday afternoon, with the NYSE Health Care Index increasing

Health care stocks were mixed Wednesday afternoon, with the NYSE Health Care Index increasing 0.1% a

Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.

Novo Nordisk stock jumps as Q1 earnings and revenues beat estimates, fueled by strong Wegovy and Ozempic demand and a raised 2026 outlook.

Private Payrolls Increased More Than Expected

Shares of Novo Nordisk (NVO), the maker of the GLP-1 drug Wegovy, popped this morning after the company reported strong demand for its new weight-loss pill.Novo Nordisk President & CEO Mike Doustdar joined Julie Hyman on Opening Bid to discuss Q1 sales and the rest of the year guidance.

Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in Chi

The Danish drugmaker is riding a wave of peptide craziness as its weight loss tablet crushes its U.S. debut.

Strong demand but earnings fall short

Novo Nordisk (NYSE:NVO) reported first-quarter results that far exceeded analyst estimates on Wednesday, driven by surging demand for its oral weight-loss pill and strong international sales. Net sales reached $15.2 billion in the quarter, well above the $11.2 billion analysts had...

Beyond obvious strength in Healthcare, we're starting to see "green shoots" in industries that a year ago were seeing negative growth.

Novo Nordisk shares climbed Wednesday after the Danish drugmaker beat estimates with its latest quarterly results.

Strong Wegovy demand lifted revenue as earnings missed estimates

Novo Nordisk stock jumped early Wednesday on a strong first-quarter report on the back of its GLP-1 drugs Wegovy and Ozempic.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1% and the actively traded

News of the day for May 6, 2026

Find insight on Novo Nordisk, Hartalega, Smith & Nephew and more in the latest Market Talks covering Health Care.

First-quarter sales of the oral Wegovy pill hit $353 million, more than double analyst expectations, as the company lifted its full-year outlook

The main US stock measures were pointing higher in Wednesday's premarket activity, while oil prices

Novo Nordisk (NYSE:NVO) raised its full-year guidance on Wednesday, citing continued strong demand for its obesity and diabetes treatments despite softer underlying first-quarter results caused by pricing pressure. The pharmaceutical group said it now expects adjusted sales and operating profit for 2026 to decline between 4% and 12% at constant exchange rates, representing a narrower contraction than previously anticipated and reflecting stronger expectations for its GLP-1 treatment portfolio.

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

Shares in Advanced Micro Devices and Intel surge after AMD CEO Lisa Su flags surging demand for central processing units.

Total prescriptions for the new Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

↗️Advanced Micro Devices (AMD): Shares of the chipmaker soared premarket after it reported stronger sales and logged higher profit. Shares of its peer Super Micro Computer Inc. (SMCI) also jumped premarket.

Shares in Wegovy maker Novo Nordisk surged this morning after it reported strong demand for its new weight-loss pill and upgraded its guidance. The Danish drugmaker said total prescriptions for the Wegovy pill reached around 1.

May 6 (Reuters) - European shares rose on Tuesday, with oil prices dropping and investor optimism rising after U.S.

Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

COPENHAGEN, May 6 () - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook ‌for the year was slightly improved. The Danish drugmaker is banking on demand for ‌its new weight-loss pill as competition with U.

VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.